Alphatec (NASDAQ:ATEC) Trading 4.8% Higher

Alphatec Holdings, Inc. (NASDAQ:ATEC)’s share price rose 4.8% during trading on Monday . The company traded as high as $5.86 and last traded at $5.86. Approximately 536,439 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 1,861,663 shares. The stock had previously closed at $5.59.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Friday, August 30th. Barclays began coverage on shares of Alphatec in a research note on Monday, July 8th. They issued an “overweight” rating and a $19.00 target price for the company. Morgan Stanley lowered shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a report on Thursday, August 1st. Finally, Needham & Company LLC reduced their price target on Alphatec from $23.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Alphatec Trading Up 3.4 %

The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The company has a market capitalization of $860.29 million, a price-to-earnings ratio of -4.27 and a beta of 1.40. The business has a fifty day moving average price of $7.70 and a 200 day moving average price of $10.42.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.03). Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The company had revenue of $145.57 million during the quarter, compared to the consensus estimate of $144.55 million. During the same period last year, the company earned ($0.43) earnings per share. Alphatec’s revenue for the quarter was up 24.5% on a year-over-year basis. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David M. Demski purchased 50,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares in the company, valued at approximately $1,635,460.47. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 22.80% of the stock is owned by company insiders.

Institutional Trading of Alphatec

Several institutional investors have recently made changes to their positions in ATEC. Comerica Bank lifted its stake in Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares during the period. Van ECK Associates Corp lifted its position in shares of Alphatec by 11.8% during the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after buying an additional 1,300 shares during the period. Tidemark LLC acquired a new stake in Alphatec in the 4th quarter valued at $137,000. EntryPoint Capital LLC bought a new stake in Alphatec in the first quarter valued at $141,000. Finally, Amalgamated Bank raised its stake in Alphatec by 7.3% during the fourth quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock worth $147,000 after acquiring an additional 660 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.